Table 6.
Use of treatment with high‐dose melphalan with stem cell support (HDT) according to comorbidity in 2190 Danish patients with newly diagnosed symptomatic multiple myeloma
| Comorbidity | All patients | Patients age ≤65 years | ||
|---|---|---|---|---|
| HDT | Other treatment | HDT | Other treatment | |
| 0 | 521 (76.1%) | 773 (51.4%) | 452 (77.7%) | 105 (57.4%) |
| 1 | 64 (9.3%) | 253 (16.8%) | 49 (8.4%) | 28 (15.3%) |
| 2 | 73 (10.7%) | 233 (15.9%) | 58 (10.0%) | 26 (14.2%) |
| ≥3 | 27 (3.9%) | 246 (16.3%) | 23 (4.0%) | 24 (13.1) |
| P a | <0.0001 | <0.0001 | ||
Comorbidity according to Charlson Comorbidity index. Chi‐square test. HDT: intention‐to‐treat.
a
HDT versus no HDT for all patients and for patients with age ≤65 years.